Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | GJA1 | P17302 | 1/20 | 0.52 |
| ▸ | GJB2 | P29033 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | HTRA2 | O43464 | 4/20 | 0.48 |
| ▸ | HTRA1 | Q92743 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14119833 | 0.95 | SLC5A2 (0.61) | SLC5A2ALBGJA1GJB2FOLH1 | |
| SCHEMBL14210372 | 0.88 | GJA1 (0.51) | SLC5A2ALBGJA1GJB2FOLH1 | |
| SCHEMBL12675193 | 0.83 | ALB (0.58) | ALBFOLH1HTRA2HTRA1CA12 | |
| SCHEMBL12040501 | 0.83 | ALB (0.57) | ALBFOLH1HTRA2HTRA1CA12 | |
| SCHEMBL12123525 | 0.82 | ALB (0.60) | SLC5A2ALBFOLH1HTRA2HTRA1 | |
| SCHEMBL17307947 | 0.81 | FOLH1 (0.58) | ALBFOLH1HTRA2HTRA1CA12 | |
| SCHEMBL13286956 | 0.81 | ALB (0.60) | ALBFOLH1HTRA2HTRA1 | |
| SCHEMBL15298994 | 0.81 | USP2 (0.58) | SLC5A2ALBFOLH1HTRA2HTRA1 | |
| SCHEMBL24062674 | 0.80 | ALB (0.59) | ALBFOLH1HTRA2HTRA1CA9 | |
| SCHEMBL18211595 | 0.80 | ALB (0.59) | ALBFOLH1HTRA2HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | SLC5A2 835/4885ALB 787/4885GJA1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.